Cargando…

2178 Drug development core facilitates institutional collaboration and translational science innovation

OBJECTIVES/SPECIFIC AIMS: Drug development is a common research pursuit for basic and clinical scientists that interfaces diagnostic/therapeutic challenges with funding agencies, pharmaceutical industry, regulatory systems, and education. The University at Buffalo Clinical and Translational Science...

Descripción completa

Detalles Bibliográficos
Autores principales: Morse, Gene, Puzanov, Igor, Gudkov, Andrei, DiFrancesco, Robin, Jusko, William, Ernstoff, Marc, Mohler, James, Murphy, Timothy, Bies, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799261/
http://dx.doi.org/10.1017/cts.2018.68
_version_ 1783460246363045888
author Morse, Gene
Puzanov, Igor
Gudkov, Andrei
DiFrancesco, Robin
Jusko, William
Ernstoff, Marc
Mohler, James
Murphy, Timothy
Bies, Robert
author_facet Morse, Gene
Puzanov, Igor
Gudkov, Andrei
DiFrancesco, Robin
Jusko, William
Ernstoff, Marc
Mohler, James
Murphy, Timothy
Bies, Robert
author_sort Morse, Gene
collection PubMed
description OBJECTIVES/SPECIFIC AIMS: Drug development is a common research pursuit for basic and clinical scientists that interfaces diagnostic/therapeutic challenges with funding agencies, pharmaceutical industry, regulatory systems, and education. The University at Buffalo Clinical and Translational Science Institute (CTSI) has implemented a Drug Development Core (DDC) with goals that foster team science and collaboration, optimize laboratory use, and networks investigators. Our goals are to foster collaborations within the region and with other CTSAs. METHODS/STUDY POPULATION: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. RESULTS/ANTICIPATED RESULTS: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. DISCUSSION/SIGNIFICANCE OF IMPACT: The CTSI DDC was well received by investigators. The request process fosters collaboration among researchers with similar interests and identifies core laboratory resources that add innovation to ongoing research, funding applications, education, and interinstitutional planning.
format Online
Article
Text
id pubmed-6799261
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-67992612019-10-28 2178 Drug development core facilitates institutional collaboration and translational science innovation Morse, Gene Puzanov, Igor Gudkov, Andrei DiFrancesco, Robin Jusko, William Ernstoff, Marc Mohler, James Murphy, Timothy Bies, Robert J Clin Transl Sci Basic/Translational Science/Team Science OBJECTIVES/SPECIFIC AIMS: Drug development is a common research pursuit for basic and clinical scientists that interfaces diagnostic/therapeutic challenges with funding agencies, pharmaceutical industry, regulatory systems, and education. The University at Buffalo Clinical and Translational Science Institute (CTSI) has implemented a Drug Development Core (DDC) with goals that foster team science and collaboration, optimize laboratory use, and networks investigators. Our goals are to foster collaborations within the region and with other CTSAs. METHODS/STUDY POPULATION: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. RESULTS/ANTICIPATED RESULTS: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. DISCUSSION/SIGNIFICANCE OF IMPACT: The CTSI DDC was well received by investigators. The request process fosters collaboration among researchers with similar interests and identifies core laboratory resources that add innovation to ongoing research, funding applications, education, and interinstitutional planning. Cambridge University Press 2018-11-21 /pmc/articles/PMC6799261/ http://dx.doi.org/10.1017/cts.2018.68 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Basic/Translational Science/Team Science
Morse, Gene
Puzanov, Igor
Gudkov, Andrei
DiFrancesco, Robin
Jusko, William
Ernstoff, Marc
Mohler, James
Murphy, Timothy
Bies, Robert
2178 Drug development core facilitates institutional collaboration and translational science innovation
title 2178 Drug development core facilitates institutional collaboration and translational science innovation
title_full 2178 Drug development core facilitates institutional collaboration and translational science innovation
title_fullStr 2178 Drug development core facilitates institutional collaboration and translational science innovation
title_full_unstemmed 2178 Drug development core facilitates institutional collaboration and translational science innovation
title_short 2178 Drug development core facilitates institutional collaboration and translational science innovation
title_sort 2178 drug development core facilitates institutional collaboration and translational science innovation
topic Basic/Translational Science/Team Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799261/
http://dx.doi.org/10.1017/cts.2018.68
work_keys_str_mv AT morsegene 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation
AT puzanovigor 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation
AT gudkovandrei 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation
AT difrancescorobin 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation
AT juskowilliam 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation
AT ernstoffmarc 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation
AT mohlerjames 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation
AT murphytimothy 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation
AT biesrobert 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation